House mark for pharmaceutical and therapeutic preparations for the treatment of patients with chronic diseases, namely, cancer, kidney disease, diabetes, cachexia, age related sarcopenia, protein-energy wasting, and multiple sclerosis; pharmaceutical and therapeutic preparations for the treatment of autoimmune diseases and disorders; none of the foregoing to be used for pharmaceutical preparations for treatment of rheumatoid arthritis and psoriasis